Literature DB >> 26803987

Total shoulder arthroplasty for proximal humerus fracture is associated with increased hospital charges despite a shorter length of stay.

A Manoli1, C E Capriccioso1, S R Konda1, K A Egol2.   

Abstract

BACKGROUND: Operation choice is a complex decision in the surgical management of proximal humerus fractures. Recently, there has been an increase in the use of total shoulder arthroplasty (TSA) for complex fracture patterns. HYPOTHESIS: Patients with proximal humerus fractures who receive TSA are more likely to have higher hospital charges and a prolonged length of stay relative to patients receiving hemiarthroplasty (HA), open reduction with internal fixation (ORIF) or closed reduction with internal fixation (CRIF).
MATERIALS AND METHODS: A statewide electronic database was used to identify 13,316 hospital admissions from 2000-2011 were a proximal humerus fracture was surgically managed in an effort to determine the effect of operation choice on cost and length of stay. A univariate analysis was preformed to examine overall trends in surgical management. Additionally, a periodic, multivariate logistic regression analysis was used to determine how operation choice affected the odds of a high cost hospital stay or a prolonged length of stay after controlling for age, comorbidity burden, gender, and insurance type.
RESULTS: After controlling for confounding factors, patients receiving total shoulder arthroplasty (TSA) were 2.25 times more likely to have high total hospital charges than patients receiving HA and 3.21 times more likely than patients receiving ORIF. Additionally, TSA was found to be a significant negative predictor of prolonged length of stay (pLOS). HA, ORIF and CRIF did not significantly predict pLOS. DISCUSSION: The use of TSA for acute proximal humerus fractures is associated with increased hospital costs despite a shorter length of stay when compared to other operative choices. As reverse total shoulder arthroplasty becomes more popular for treatment of this injury, it is important that functional outcomes be interpreted in the context of relative cost trade-offs. LEVEL OF EVIDENCE: Level IV.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cost; Hemiarthroplasty; Length of stay; Proximal humerus fracture; Total shoulder arthroplasty

Mesh:

Year:  2016        PMID: 26803987     DOI: 10.1016/j.otsr.2015.11.003

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  5 in total

1.  Comorbidity effects on shoulder arthroplasty costs analysis of a nationwide private payer insurance data set.

Authors:  Samuel Rosas; Karim G Sabeh; Leonard T Buller; Tsun Yee Law; Steven P Kalandiak; Jonathan C Levy
Journal:  J Shoulder Elbow Surg       Date:  2017-01-27       Impact factor: 3.019

2.  Treatment of humerus fractures in the elderly: A systematic review covering effectiveness, safety, economic aspects and evolution of practice.

Authors:  Cecilia Mellstrand Navarro; Agneta Brolund; Carl Ekholm; Emelie Heintz; Emin Hoxha Ekström; Per Olof Josefsson; Lina Leander; Peter Nordström; Lena Zidén; Karin Stenström
Journal:  PLoS One       Date:  2018-12-13       Impact factor: 3.240

3.  ORIF versus arthroplasty for open proximal humerus fractures: Nationwide Inpatient Sample data between 1998 and 2013.

Authors:  Anant Dixit; Frank S Cautela; Colin S Cooper; George A Beyer; James C Messina; Jeffrey E Mait; Neil V Shah; Bassel G Diebo; Carl B Paulino; William P Urban
Journal:  J Orthop Traumatol       Date:  2018-08-22

4.  Shoulder Arthroplasty for the Treatment of Proximal Humeral Fractures: Current Concepts.

Authors:  Geraldo da Rocha Motta Filho; Marcus Vinícius Galvão Amaral
Journal:  Rev Bras Ortop (Sao Paulo)       Date:  2021-03-31

5.  Outcome of geriatric proximal humeral fractures: a comparison between reverse shoulder arthroplasty versus open reduction and internal fixation.

Authors:  Nadine Ott; Carolin Müller; Andreas Jacobs; Christian Paul; Kilian Wegmann; Lars Peter Müller; Koroush Kabir
Journal:  OTA Int       Date:  2022-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.